Eagle and Cognizant partner with Pistoia Alliance for sequence services

NewsGuard 100/100 Score

Cognizant (NASDAQ: CTSH), a leading provider of consulting, technology, and business process outsourcing services, and Eagle Genomics Ltd., a bioinformatics software company specializing in genomic data management and integration, today announced they are working with the Pistoia Alliance, Inc., a nonprofit, precompetitive alliance of life science companies and vendors, as one of the groups engaged to develop a conceptual cloud-based platform to facilitate access to public and proprietary sources of gene sequence data.

The Pistoia Alliance's sequence services working group aims to define and document an externally hosted service for securely storing and mining both proprietary derived gene/sequence information and public domain gene databases. This conceptual platform developed by Cognizant and Eagle Genomics, as part of this piloting stage, will enable working group companies to securely share their bioinformatics resources among simultaneous, registered users in a secure, encrypted environment, while leveraging the flexibility, scalability, and cost-efficiencies of a cloud-based Software as a Service (SaaS) platform. The future of collaboration and externalization within the life sciences industry will increasingly utilize hosted information services, and the Pistoia Alliance expects to run future pilots to further explore this business model involving a range of participants.

"This engagement supports the Pistoia Alliance's goal to inspire different ways of thinking in the life sciences industry and effect real change to benefit all our organizations," said Nick Lynch, President at Pistoia Alliance. "With the combined strengths of Cognizant and Eagle Genomics and the broader Pistoia community, we will build a platform to define standards in sequence services, while overcoming the challenges of disparate data and tools."

Cognizant and Eagle Genomics will combine the best of their consulting, domain, technology, and business process expertise to effectively deliver the business solution. While Eagle Genomics will contribute specialized bioinformatics knowledge, Cognizant will manage the development of the platform, oversee testing and security validation, and help strengthen the initiative by managing relationships with existing and potential member organizations. The platform will deploy a secure and scalable installation of Ensembl, a software system and supporting database developed jointly by the Wellcome Trust Sanger Institute and the European Bioinformatics Institute to produce and maintain automatic annotation on selected eukaryotic genomes. The platform will deliver a Plasmapper and a gene alias service as part of the initial functional services.

"Eagle and Cognizant have demonstrated a deep understanding of the open-source bioinformatics world and how best to adapt and support these publicly available resources to meet the high standards required by the leading pharmaceutical companies that are members of the Pistoia Alliance," said Richard Holland, co-founder and Operations and Delivery Director at Eagle Genomics Ltd.

"We look forward to partnering with Eagle Genomics in helping Pistoia Alliance address the challenges of fast evolving sequence services while streamlining communication and workflows," said Peter Sheppard, Assistant Vice President, Life Sciences practice at Cognizant. "We are committed to leveraging our domain-intensive global resources, deep understanding of drug development processes and cloud computing models, and global program management and delivery capabilities to build and manage a platform that supports the Pistoia Alliance's aim to lower barriers to innovation by improving the interoperability of business processes, data, and technology interfaces in the life sciences research industry."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles